Bellerophon Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.87 Insider Own1.70% Shs Outstand9.55M Perf Week25.15%
Market Cap10.38M Forward P/E- EPS next Y-1.90 Insider Trans0.00% Shs Float9.22M Perf Month-47.26%
Income-17.80M PEG- EPS next Q-0.57 Inst Own32.70% Short Float0.33% Perf Quarter-53.71%
Sales- P/S- EPS this Y41.10% Inst Trans- Short Ratio0.55 Perf Half Y-70.47%
Book/sh1.69 P/B0.63 EPS next Y-6.30% ROA-61.30% Target Price24.50 Perf Year-74.15%
Cash/sh2.04 P/C0.52 EPS next 5Y- ROE-76.60% 52W Range0.67 - 5.95 Perf YTD-65.81%
Dividend- P/FCF- EPS past 5Y39.80% ROI- 52W High-82.18% Beta-0.04
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low58.21% ATR0.17
Employees20 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)34.48 Volatility16.12% 14.78%
OptionableNo Debt/Eq0.00 EPS Q/Q-2.70% Profit Margin- Rel Volume0.96 Prev Close0.96
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume54.45K Price1.06
Recom2.00 SMA20-18.86% SMA50-41.11% SMA200-63.57% Volume52,090 Change9.96%
Aug-11-20Initiated Jefferies Buy $19
Jan-24-19Initiated Maxim Group Buy $3
Apr-17-17Initiated Ladenburg Thalmann Buy $4.50
Jan-20-17Initiated H.C. Wainwright Buy $5
Mar-22-16Reiterated Leerink Partners Outperform $11 → $9
Jul-27-15Reiterated FBR Capital Outperform $23 → $11
Mar-16-15Initiated FBR Capital Outperform $23
May-12-22 08:30AM  
May-11-22 08:30AM  
Mar-31-22 04:01PM  
Mar-02-22 04:32AM  
Jan-10-22 07:00AM  
Dec-17-21 08:30AM  
Dec-01-21 10:00AM  
Nov-15-21 08:30AM  
Sep-07-21 08:30AM  
Sep-03-21 08:16AM  
Aug-05-21 08:30AM  
Jun-29-21 08:05AM  
Jun-18-21 11:08AM  
Jun-09-21 10:28AM  
May-27-21 08:30AM  
May-26-21 08:30AM  
May-20-21 10:14AM  
May-11-21 08:30AM  
Mar-11-21 08:30AM  
Mar-02-21 08:30AM  
Jan-04-21 08:30AM  
Dec-01-20 08:30AM  
Nov-28-20 08:49PM  
Nov-23-20 08:30AM  
Nov-11-20 08:30AM  
Nov-05-20 10:05AM  
Oct-29-20 08:30AM  
Sep-14-20 11:49AM  
Aug-11-20 08:30AM  
Aug-05-20 08:30AM  
Jul-15-20 08:30AM  
Jul-13-20 08:30AM  
Jun-29-20 08:00AM  
Jun-04-20 06:42PM  
May-29-20 03:40PM  
May-22-20 09:47AM  
May-19-20 06:53PM  
May-18-20 04:03PM  
May-12-20 10:09AM  
May-11-20 04:01PM  
May-04-20 08:30AM  
Apr-17-20 12:19PM  
Apr-08-20 08:23PM  
Apr-06-20 10:23AM  
Apr-01-20 01:06PM  
Mar-31-20 08:30AM  
Mar-30-20 09:57AM  
Mar-29-20 03:44PM  
Mar-23-20 09:30AM  
Mar-22-20 08:19AM  
Mar-20-20 08:30AM  
Mar-10-20 08:30AM  
Feb-21-20 12:11PM  
Feb-19-20 10:32AM  
Feb-18-20 08:30AM  
Feb-07-20 12:00PM  
Dec-20-19 04:18PM  
Dec-17-19 08:44AM  
Nov-12-19 08:30AM  
Nov-07-19 08:30AM  
Nov-06-19 08:30AM  
Nov-01-19 11:51AM  
Oct-28-19 07:15AM  
Oct-23-19 08:30AM  
Oct-20-19 08:08AM  
Oct-14-19 08:30AM  
Sep-16-19 08:30AM  
Sep-04-19 08:30AM  
Aug-08-19 12:57PM  
Aug-06-19 08:15PM  
Aug-01-19 08:30AM  
Jun-13-19 08:00AM  
May-22-19 08:30AM  
May-21-19 08:30AM  
May-18-19 09:50AM  
May-13-19 08:30AM  
May-09-19 08:45AM  
May-03-19 12:10PM  
Apr-08-19 08:30AM  
Mar-18-19 02:08PM  
Mar-14-19 09:09AM  
Jan-28-19 08:30AM  
Jan-25-19 04:05PM  
Jan-23-19 06:00AM  
Jan-22-19 04:44PM  
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.